T W Synold
Overview
Explore the profile of T W Synold including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
674
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Synold T, Xi B, Newman E, Muggia F, Doroshow J
J Chromatogr B Biomed Appl
. 1996 Aug;
683(2):245-9.
PMID: 8891922
Previously described methods for the determination of lometrexol in plasma used either fluorescence or ultraviolet detection. An alternative method for the determination of lometrexol utilizing electrochemical detection is described, having...
22.
Synold T, Willits E, Barredo J
Leuk Lymphoma
. 1996 Mar;
21(1-2):9-15.
PMID: 8907263
Even though folate antimetabolites were introduced over forty years ago, they continue to be the backbone of many active chemotherapeutic regimens used by medical and pediatric oncologists. The recognition of...
23.
Synold T, Doroshow J
J Infus Chemother
. 1996 Jan;
6(2):69-73.
PMID: 8809652
In this review, the clinical pharmacology of high-dose doxorubicin is examined, and the pharmacokinetics of infusional doxorubicin at standard and high dose are compared. The data developed here, including recent...
24.
Masson E, Synold T, Relling M, Schuetz J, Sandlund J, Pui C, et al.
Leukemia
. 1996 Jan;
10(1):56-60.
PMID: 8558939
Allopurinol is used to prevent hyperuricemia in newly diagnosed patients with acute lymphoblastic leukemia (ALL). Although allopurinol has been shown to inhibit de novo purine synthesis (DNPS) in fibroblasts in...
25.
Masson E, Relling M, Synold T, Liu Q, Schuetz J, Sandlund J, et al.
J Clin Invest
. 1996 Jan;
97(1):73-80.
PMID: 8550853
Methotrexate (MTX) is one of the most widely used drugs for the treatment of childhood acute lymphoblastic leukemia (ALL) and is commonly given in high doses. However, the rationale for...
26.
Murry D, Synold T, Pui C, Rodman J
Pharmacotherapy
. 1995 Mar;
15(2):144-9.
PMID: 7624260
Study Objectives: To determine whether glomerular filtration rate (GFR) changes during induction chemotherapy in children with leukemia, and to examine GFR as a determinant of pharmacokinetic variability of methotrexate clearance....
27.
Synold T, Relling M, Boyett J, Rivera G, Sandlund J, Mahmoud H, et al.
J Clin Invest
. 1994 Nov;
94(5):1996-2001.
PMID: 7525652
High-dose methotrexate (HDMTX) is a component of most treatment protocols for childhood acute lymphoblastic leukemia (ALL), yet recent studies of receptor-mediated transport and saturable polyglutamylation have questioned its rationale. To...
28.
Barredo J, Synold T, Laver J, Relling M, Pui C, Priest D, et al.
Blood
. 1994 Jul;
84(2):564-9.
PMID: 7517720
Folylpolyglutamate synthetase (FPGS) is responsible for the metabolism of natural folates and a broad range of folate antagonists to polyglutamate derivatives. Recent studies indicated increased accumulation of methotrexate (MTX) polyglutamates...
29.
Rodman J, Relling M, Stewart C, Synold T, McLeod H, Kearns C, et al.
Semin Oncol
. 1993 Feb;
20(1):18-29.
PMID: 8475406
Pharmacokinetic variability in children with cancer is substantial and confounds drawing conclusions regarding optimal therapy based only on dose-response relationships. Careful pharmacokinetic studies performed during drug development in conjunction with...
30.
Houghton P, Cheshire P, Myers L, Stewart C, Synold T, HOUGHTON J
Cancer Chemother Pharmacol
. 1992 Jan;
31(3):229-39.
PMID: 1464161
The topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin (topotecan) was evaluated against a panel of xenografts comprising four lines of adult colon adenocarcinoma, three colon tumors derived from adolescents, six childhood rhabdomyosarcomas from...